Cipla Shares Surge 4% as Citi Forecasts Major Growth Catalysts

Cipla shares witnessed a significant rally on the BSE, jumping as much as 4% to reach a high of Rs 1,409 following a bullish update from Citi. The international brokerage has placed the pharmaceutical giant on a "90-day Positive Catalyst Watch," maintaining a 'Buy' rating with a target price of Rs 1,700, implying a potential upside of over 25%.

Near-Term Triggers in the US Market

A primary driver behind Citi's optimism is the series of upcoming regulatory and product milestones in the United States. The brokerage highlighted the anticipated approval of gFlovent from Cipla's Goa facility, which is expected to significantly bolster growth in the US market. Furthermore, the expected launch of gVentolin serves as another key catalyst.

Cipla's US operations are also showing signs of a robust recovery after a period of weakness. Notably, the company's Nintedanib has already successfully captured nearly 50% of the market share in the US. Additionally, the potential re-inspection of the Indore plant by the USFDA could act as a major positive trigger if the outcome is favorable.

Domestic Strength and Valuation Advantages

While the US market provides growth triggers, Cipla's domestic business remains a fundamental pillar of its stability. The India business currently contributes nearly two-thirds of the company's EBITDA, supported by a strong recovery in its respiratory portfolio.

From a valuation perspective, Citi suggests that Cipla offers a more attractive entry point compared to its domestic-focused peers. For instance, Cipla's India business is valued at 7.8 times FY26 sales, which is more reasonable than Mankind Pharma, which trades at 8.5 times. With geopolitical tensions easing and raw material costs stabilizing, margins are expected to see relief. Citi also believes that Cipla's earnings have likely bottomed out following the impact of gRevlimid.

Analyzing Recent Financial Performance

Despite the optimistic outlook, Cipla's recent quarterly results showed significant volatility. In the fourth quarter, the company reported a 55% year-on-year (YoY) decline in consolidated net profit, falling to Rs 555 crore from Rs 1,222 crore in the same period last year. Revenue from operations also saw a minor dip of approximately 3% YoY to Rs 6,541 crore.

The EBITDA margin also experienced a contraction, dropping to 15.2% from 22.8% in the previous year. For the full financial year ending March 31, 2026, Cipla reported a 2% YoY rise in revenue to Rs 28,163 crore, though net profit declined by 26% to Rs 3,879 crore. However, the brokerage views these past hurdles as settled, focusing instead on the upcoming revenue rebound and improved risk-reward profile.

Key Takeaways

• Bullish Outlook: Citi has set a target price of Rs 1,700 for Cipla, suggesting a 25.55% upside based on upcoming US and domestic catalysts.
• US Market Growth: Key triggers include the expected launch of gVentolin, gFlovent approval from the Goa facility, and Nintedanib's 50% US market share.
• Attractive Valuation: Compared to peers like Mankind, Cipla offers a more reasonable valuation for its India-focused business, which drives two-thirds of its EBITDA.